Female Urology

New York-Recently published data could better help diagnose and select treatments for infertile couples, targeting treatments likely to work and perhaps sparing some patients invasive, high-cost treatments less likely to prove effective.

Cleveland-Although skeletal fractures attributed to androgen suppressionare present in a small percentage of men on the therapy, the incidence maybe as high as five times that of the normal population, according to VincentS. Ricchiuti, MD, chief resident, department of urology, Case Western Reserve-UniversityHospitals, Cleveland.

Toronto-Not unlike many of the patients seen in urology practices, a significant percentage of young infertile men take alternative therapies, some of which may adversely affect their fertility. But many of these men may be hesitant to share this information with you.

Boston-Perhaps offering a measure of reassurance to prostatitis patientsand their urologists, data from a prospective study suggest that the symptomsof chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) typicallyimprove or remain stable over time. During a 1-year follow-up of a cohort receiving "usual care"for their symptoms, half the patients had symptom improvement, and morethan one-third reported their symptoms unchanged. Symptoms deterioratedin about 14% of patients.

New York-The young, otherwise healthy men urologists see for an infertility evaluation may be hiding a condition more commonly observed in older men and women. Researchers from the Cornell Institute of Reproductive Medicine in New York report that three-fourths of men with nonobstructive azoospermia, a severe form of male infertility, are at risk for significant bone loss.

Baltimore-For the first time, urologists and gynecologists have the basis for a unified approach to the management of male infertility in a series of four practice policies jointly produced by AUA and the American Society for Reproductive Medicine.

Washington-MDLinx now offers www.urologylinx.com, a web site featuring news about general urology and urologic subspecialties. The site's subspecialties include adrenal glands, erectile dysfunction, infertility, kidney, pediatric urology, penis, prostate, stones, testis/scrotum, ureter, urethra, urinary bladder, uroradiology, voiding dysfunction, basic science/genetics, economics of medicine, and popular press.

Many prostate cancer researchers were delighted last fall by two significant developments. First, Myriad Genetics, a Salt Lake City-based biopharmaceutical company, announced on October 4 that its research team had cloned a prostate cancer susceptibility gene (HPC2), also known as ELAC2. That same month, an independent research team at the University of Pennsylvania published its findings that the variant allele (copy) of the gene was found to be more common in men with prostate cancer than in healthy matched controls.